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Our knowledge of the host genetic factors that contribute to the acquisition of HIV infection is limited. To
identify the host genetic correlates of HIV1 acquisition, we genotyped 777 participants of a randomized
trial of recombinant adenovirus HIV1 vaccine for Fcγ receptor IIa (FcγRIIa), FcγRIIIa, and several GM and
KM alleles—genetic markers of immunoglobulin γ and κ chains, respectively. None of the genotypes by
itself was signiﬁcantly associated with the acquisition of HIV1 infection. However, particular combina-
tions of GM and KM as well as those of GM and FcγRIIIa loci were signiﬁcantly associated with the
acquisition of HIV1 infection epistatically: KM1/3-GM3/17 (interaction p¼0.0246; FDR¼0.2952), KM1/3-
GM5/21 (interaction p¼0.0016; FDR¼0.0960), and GM23þ/−FcγRIIIa (interaction p¼0.0060;
FDR¼0.1200). These results suggest the involvement of GM, KM, and FcγRIIIa loci in the acquisition of
HIV infection. Additional studies are warranted.
& 2013 Elsevier Inc. All rights reserved.Introduction
The Step trial – a test-of-concept study that used the MRKAD5
HIV1 gag/pol/nef vaccine – was prematurely terminated because
the vaccine was not only ineffective in lowering the post-infection
viral load but it also increased the risk of HIV1 acquisition in the
vaccines compared to the placebo group (Buchbinder et al., 2008).
For future development of an effective vaccine that could either
lower viremia or HIV1 infection rates, it is important to under-
stand the factors responsible for this disappointing outcome.
Towards this endeavor, we tested the hypothesis that host genetic
factors might have, at least partially, contributed to the risk of
HIV1 acquisition. GM and KM allotypes – antigenic determinants
of IgG heavy chains and κ-type light chains, coded by IGHG and IGK
loci, respectively – are involved in the immunobiology of several
viruses (Atherton et al., 2000; Namboodiri and Pandey, 2011;
Pandey et al., 2004, 2008), but their role as possible genetic
correlates of HIV1 acquisition has hitherto not been examined.
The aim of this investigation was to determine whether GM and
KM genes – individually or epistatically – contributed to the risk of
HIV1 acquisition. The majority of the GM markers are expressed in
the Fc region of Ig γ1, γ2, and γ3 chains, thus making them the
most likely candidates in the genome for epistatic interactionsll rights reserved.with FcγR genes, which have been implicated in HIV susceptibility,
antibody-dependent cell-mediated virus inhibition (ADCVI), and
disease progression (Forthal et al., 2007a, 2007b; Poonia et al.,
2010). Therefore, we examined both the individual and interactive
effects of GM and FcγR alleles on the acquisition of HIV1 infection
in the Step trial participants.Results
The distribution of GM, KM, and FcγR genotypes between HIV
infected and HIV uninfected white subjects as well as all partici-
pants, assuming the dominant model of inheritance, is presented
in Tables 1 and 2, respectively. None of the genotypes by itself was
signiﬁcantly associated with the acquisition of HIV1 infection,
irrespective of the treatment status (placebo vs. vaccine). Analyses,
assuming the additive model of inheritance, concurred with these
results (data not shown).
The distribution of particular combinations of GM, KM, and
FcγR genotypes between HIV infected and HIV uninfected white
subjects as well as all participants, assuming the dominant model
of inheritance, is presented in Tables 3 and 4, respectively. In white
participants, compared to those who were homozygous for KM
3 and GM 17 alleles, KM1-carriers and GM17 homozygotes were
over six times more likely to acquire HIV infection (HR¼6.21;
p¼0.0237; Table 3). Interaction p-value and false discovery rate
(FDR) among all possible pairs of interactions being tested were
Table 1
Distribution of GM, KM, and FcγR genotypes between HIV infected and HIV
uninfected white subjects.
Genotype HIV infected Hazard ratio
Yes N (%) No N (%) Estimate (95%CI) p-value
KM1/3
KM3/3 42 (75) 135 (80) 1 –
KM1 carrier 14 (25) 34 (20) 1.42 (0.56, 3.61) 0.4583
GM3/17
GM17/17 11 (20) 25 (15) 1 –
GM3 carrier 45 (80) 142 (85) 0.79 (0.31, 2.04) 0.6303
GM5/21
GM5/5 28 (50) 77 (46) 1 –
GM21 carrier 28 (50) 91 (54) 0.78 (0.39, 1.55) 0.479
GM23þ/−
GM23−/− 21 (38) 55 (33) 1 –
GM23þcarrier 35 (62) 114 (67) 1.18 (0.50, 2.79) 0.6978
FcγRIIa
H/H 13 (23) 38 (22) 1 –
R-carrier 43 (77) 131 (78) 0.92 (0.39, 2.15) 0.8462
FcγRIIIa
F/F 29 (52) 81 (48) 1 –
V-carrier 27 (48) 88 (52) 0.88 (0.46, 1.72) 0.7176
Table 2
Distribution of GM, KM, and FcγR genotypes between all HIV infected and HIV
uninfected subjects.
Genotype HIV infected Hazard ratio
Yes N (%) No N (%) Estimate (95%CI) p-value
KM1/3
KM3/3 67 (62) 235 (65) 1 –
KM1 carrier 41 (38) 124 (35) 1.36 (0.81, 2.27) 0.2396
GM3/17
GM17/17 34 (32) 142 (40) 1
GM3 carrier 73 (68) 215 (60) 1.09 (0.59, 2.02) 0.7741
GM5/21
GM5/5 44 (41) 145 (41) 1 –
GM21 carrier 63 (59) 213 (59) 1.21 (0.71, 2.07) 0.4829
GM23þ/−
GM23−/− 58 (54) 193 (54) 1 –
GM23þcarrier 50 (46) 166 (46) 1.14 (0.67, 1.95) 0.6215
FcγRIIa
H/H 24 (22) 70 (20) 1 –
R-carrier 84 (78) 288 (80) 0.89 (0.52, 1.53) 0.6828
FcγRIIIa
F/F 56 (52) 177 (49) 1 –
V-carrier 52 (48) 182 (51) 0.94 (0.61, 1.45) 0.7862
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was not signiﬁcant when data from all participants were com-
bined, the interaction p-value and FDR being 0.507 and 0.981,
respectively (Table 4). There appears to be an additive effect of
KM1 on infection status in white subjects as well as in all
participants (Table 5). In subjects lacking GM3, presence of one
additional KM allele increases the infection risk by ﬁve fold
(HR¼5.01; p¼0.0282) in white subjects and over two fold in all
participants (HR¼2.13; p¼0.0365).
There was no signiﬁcant interactive effect of KM1/3 and GM5/
21 genotypes in white subjects for either the dominant (Table 3)
or the additive (Table 5) model of inheritance. For the combined
data of all participants, however, this interaction was signiﬁcant
for the dominant (p¼0.0016; Table 4) and the additive model
of inheritance (p¼0.0052; Table 5). Compared to having a KM1
allele or a GM21 allele alone, presence of both KM1 and GM21
alleles increased the risk of HIV infection over two fold (HR¼2.16;
Table 5).GM23 and FcγRIIIa genotypes, assuming the dominant model,
interacted signiﬁcantly and contributed to the risk of HIV1
acquisition in white subjects (p¼0.0060; FDR¼0.12; Table 3) and
also when all data were combined (p¼0.0085; FDR¼0.1275;
Table 4). Compared to white subjects who were homozygous for
GM23- and FcγRIIIa F alleles, GM23-carriers and FcγRIIIa F homo-
zygotes were over four times more likely to acquire HIV1 infection
(HR¼4.34; p¼0.0275; Table 3), and those who were homozygous
for the GM23-allele and carried the FcγRIIIa V allele were also over
four times more likely to acquire HIV1 infection (HR¼4.11;
p¼0.0436; Table 3). In the combined data, GM23-carriers and
FcγRIIIa F homozygotes were over twice as likely to acquire HIV1
infection as those who were homozygous for the GM23- and
FcγRIIIa F alleles (HR¼2.47; p¼0.0264; Table 4). Interactions
between these genotypes were not signiﬁcant for the additive
model of inheritance (Table 5). The Kaplan–Meier plots of survival
curves for all three pairs of gene–gene combinations are shown in
Supplement Figs. S1–S3. There was no evidence to suggest an
interaction between the genotypes and the vaccine treatment
status (data not shown).Discussion
We found that subjects who were homozygous for the GM17
variant in the γ1 gene were at higher risk of HIV1 acquisition if
they also carried the κ chain determinant KM 1 compared to those
who lacked this determinant (i.e. KM 3 homozygotes). One
mechanism by which GM and KM allotypes could inﬂuence the
acquisition of HIV1 infection is by regulating the titer and afﬁnity
of antibodies directed against the viral epitopes. Perhaps the B-cell
membrane bound IgG expressing the GM17/17 and KM 1/1 or 1,3
speciﬁcities constitutes a lower afﬁnity receptor for the critical
epitopes of HIV1 than the one with KM 3/3, resulting in weak
humoral response to this pathogen. Similar mechanisms can be
postulated to explain the observed interactive effects of KM and
GM5/21 genotypes.
In addition to their possible role in humoral immunity, GM
allotypes could also contribute to the acquisition of HIV1 infection
by inﬂuencing the magnitude of cellular immunity to this patho-
gen. These determinants – either individually or epistatically with
certain HLA and KM alleles – are associated with several cell-
meditated immune functions (Legrand et al., 1982; Schmidt et al.,
1987; Wachsmuth et al., 1987).
Since this is the ﬁrst study of this type for HIV infection, these
results cannot be compared directly with other studies. None-
theless, it is relevant to note that GM and KM allotypes interac-
tively contribute to the outcome of infection with hepatitis C virus
(HCV), a frequent co-infection with HIV (Pandey et al., 2004). They
also are associated with antibody responsiveness to the HCV
glycoproteins E1E2 (Pandey et al., 2008). Signiﬁcant interaction
between particular GM and KM alleles may be a reﬂection of
preferential association of γ and κ chains expressing these alleles
in the synthesis of IgG antibodies directed against particular
epitopes. Such non-random associations between γ and κ chains
have been reported in experimental animals (Czerwinski et al.,
1998; Primi et al., 1987).
We also found that subjects who were homozygous for the F
variant of the FcγRIIIa gene were at higher risk of HIV1 acquisition
if they also carried the γ2 chain determinant GM23, compared to
those who lacked this determinant. Likewise, among subjects
lacking GM23, carriers of the V allele of FcγRIIIa gene were at
higher risk of HIV1 acquisition than non-carriers (i.e. F/F homo-
zygotes). A plausible mechanism underlying this association could
involve epistatic contribution of these genes to the ADCC of
HIV-infected cells, ADCVI or other Fc-mediated effector functions,
Table 3
Distribution of particular GM3/17-KM1/3, GM5/21-KM1/3, and FcγRIIIa-GM23þ/-genotype combinations in relation to HIV infection status in white subjects.
Genotype HIV infected No Hazard ratio p-value
Combination Yes N (%) estimate
N (%) (95%CI)
KM – GM3/17
KM3/3, GM17/17 5 (9) 21 (13) 1 –
KM1 carrier, GM17/17 6 (11) 4 (2) 6.21 (1.28, 30.21) 0.0237
KM3/3, GM3 carrier 37 (66) 112 (67) 1.53 (0.46, 5.13) 0.492




Interaction p-value (FDR) 0.0246 (0.2952)
KM – GM5/21
KM3/3, GM5/5 24 (43) 60 (36) 1 –
KM1 carrier, GM5/5 4 (7) 17 (10) 0.64 (0.16, 2.56) 0.5238
KM3/3, GM21 carrier 18 (32) 74 (44) 0.54 (0.25, 1.19) 0.1277
KM1carrier, GM21 carrier 10 (18) 17 (10) 1.42 (0.49, 4.11) 0.5144
KM1nGM21
Interaction p-value (FDR) 0.0890 (0.5340)
GM23 – FcγRIIIa
GM23−/−, F/F 5 (9) 23 (14) 1 –
GM23þcarrier, F/F 24 (43) 58 (34) 4.34 (1.18, 15.98) 0.0275
GM23−/−, V carrier 16 (29) 32 (19) 4.11 (1.04, 16.23) 0.0436
GM23 carrier, V carrier 11 (20) 56 (33) 1.70 (0.43, 6.80) 0.4513
GM23þnV
Interaction p-value (FDR) 0.0060 (0.1200)
Table 4
Distribution of particular GM3/17-KM1/3, GM5/21-KM1/3, and FcγRIIIa-GM23þ/– genotype combinations in relation to HIV infection status in all subjects.
Genotype HIV infected Hazard ratio
Combination Yes No Estimate p-value
N (%) N (%) (95%CI)
KM – GM3/17
KM3/3, GM17/17 16 (15) 77 (21) 1 –
KM1 carrier, GM17/17 18 (17) 65 (18) 1.79 (0.72, 4.43) 0.2085
KM3/3, GM3 carrier 50 (47) 156 (44) 1.26 (0.59, 2.68) 0.5435
KM1carrier, GM3 carrier 23 (21) 59 (17) 1.55 (0.59, 4.02) 0.3714
KM1nGM3
Interaction p-value (FDR) 0.5067 (0.9807)
KM – GM5/21
KM3/3, GM5/5 34 (32) 90 (25) 1 –
KM1 carrier, GM5/5 10 (9) 55 (16) 0.42 (0.15, 1.18) 0.0994
KM3/3, GM21 carrier 32 (30) 144 (40) 0.66 (0.36, 1.24) 0.1991
KM1carrier, GM21carrier 31 (29) 69 (19) 1.88 (0.93, 3.79) 0.0779
KM1nGM21
Interaction p-value (FDR) 0.0016 (0.0960)
GM23 – FcγRIIIa
GM23−/−, F/F 24 (22) 100 (28) 1 –
GM23þcarrier, F/F 32 (30) 77 (21) 2.47 (1.11, 5.49) 0.0264
GM23−/−, V carrier 34 (31) 93 (26) 1.77 (0.88, 3.57) 0.1102
GM23 carrier, V carrier 18 (17) 89 (25) 1.14 (0.50, 2.63) 0.7506
GM23þnV
Interaction p-value (FDR) 0.0085 (0.1275)
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envelope proteins – the usual targets of Fc-mediated effector
functions – it did include the nef protein, whose antibody-
inducing epitopes are exposed on the surface of HIV-infected cells
(Yamada and Iwamoto, 1999). The nef-induced antibodies could
mediate effector functions, such as ADCC. It is relevant to note that
we have found interactive effects of particular GM and FcγR
genotypes on the control of HIV1 replication (Deepe et al., 2011).
It is also possible that the associations we have observed are
due to linkage disequilibrium between particular GM, KM, and
FcγR alleles and alleles of other loci, as-yet-unidentiﬁed, for innate
immunity to HIV. In contrast to the results reported by Poonia
et al. (2010), we did not ﬁnd a signiﬁcant association between
FcγRIIIa alleles and HIV1 acquisition. The two studies, however, are
not comparable. The former involved African Americans only,while the present study consisted of several ethnicities, including
African Americans. Also, the HIV uninfected controls in the
study by Poonia et al. may or may not have been at high risk
of HIV1 acquisition, whereas all subjects in the present study
were.
Although epistatic effects of particular genotypes on HIV1
acquisition reported here are strong, they could be due to chance
ﬂuctuations, as the p values were not adjusted by Bonferroni’s
method. Such adjustment is controversial (Perneger, 1998) and,
given the absolute linkage disequilibrium between certain GM
alleles within a race and signiﬁcant linkage disequilibrium between
particular FcγRIIa and FcγRIIIa alleles, it would likely be overly
punitive. We have thus computed the FDR for all gene–gene
interactions. For an exploratory study like ours, the FDRs in
Tables 3 and 4 appear borderline signiﬁcant. Certainly, the best
Table 5
Interactions from particular GM-KM and GM-FcγR genotype combinations in
relation to HIV infection status based on additive models for genotypes.




Combination estimate p-value estimate p-value
(95%CI) (95%CI)
KM – GM3/17
KM1 5.01 (1.19, 21.11) 0.0282 2.13 (1.05, 4.31) 0.0365
GM3 1.35 (0.72, 2.52) 0.3451 1.22 (0.80, 1.86) 0.3626
KM1nGM3 0.33 (0.10, 1.15) 0.0825 0.65 (0.35, 1.20) 0.1667
Interaction FDR 0.6188 0.6668
KM – GM5/21
KM1 0.66 (0.14, 3.21) 0.6073 0.78 (0.36, 1.68) 0.5286
GM21 0.62 (0.34, 1.15) 0.1331 0.77 (0.49, 1.20) 0.2495
KM1nGM21 3.29 (0.82, 13.27) 0.0939 2.16 (1.26, 3.71) 0.0052
Interaction FDR 0.4695 0.1560
GM23 – FcγRIIIa
GM23þ 1.62 (0.87, 3.00) 0.1251 1.55 (0.93, 2.57) 0.0896
V 1.28 (0.51, 3.27) 0.5985 1.30 (0.77, 2.19) 0.3293
GM23þnV 0.57 (0.21, 1.54) 0.2687 0.63 (0.35, 1.15) 0.1319
Interaction FDR 0.8485 0.6088
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and preferably larger – sample. The results presented here also
underscore the importance of measuring gene–gene (epistasis)
interactions, which is usually overlooked in most genetic studies.
Genes do not act in isolation: there is increasing evidence that
modiﬁcation of the action of a gene by one or more other genes
plays a signiﬁcant role in human diseases. Epistatic interactions
could account for a signiﬁcant portion of genetic variance under-
lying the inter-individual disparity in the acquisition of HIV1
infection. Finally, numerous studies have been conducted to
identify the host genetic determinants of viral load and the
progression of HIV infection, but there is a paucity of studies aimed
at identifying genes that contribute to the acquisition of HIV
infection. Such studies may identify novel pathways of immunity
to HIV infection.Materials and methods
Patient samples
The experimental design of the Step study has been described
in detail elsewhere (Buchbinder et al., 2008). All participants were
at high risk of HIV1 acquisition on the basis of reported risk
behavior (Buchbinder et al., 2008). For the current investigation,
samples were selected based on a predeﬁned cohort and modiﬁed
based on sample availability. The original protocol measured
immunogenicity in a random sample of 25% of study participants,
stratiﬁed on treatment status and study site. These participants,
plus subjects not in the random sample who were HIV1 infected as
of January 2009, were initially selected for testing. Revisions were
then made to the sampling list due to specimen availability issues.
A total of 777 participants were genotyped. The majority of
infection in the Step study occurred in males, so this analysis
was restricted to male participants. Population stratiﬁcation due to
admixture can lead to both false-positive and false-negative
associations. Therefore, the primary analysis was limited to parti-
cipants who self-reported as white only, the only ethnic group
with sufﬁcient sample size for appropriate analyses. The data for
white male participants include 225 subjects, 169 who were
uninfected and in the sampling cohort, 20 who were infected
and in the sampling sub-cohort, and 36 who were infected and not
in the sampling cohort, where infection status was as of May 2011.Additional analyses included all male participants, but were
adjusted for the racial categories in the regression model.
GM and KM genotyping
For the determination of IgG1 allelic markers GM3 and 17
(arginine to lysine substitution, a G to A transition in the CH1 region
of the γ1 gene), a direct DNA sequencing method was used. The DNA
segment encoding the CH1 region of γ1 chain was ampliﬁed by PCR
according to Balbín et al. (1991), using the following primers: 5′
CCCCTGGCACCCTCCTCCAA 3′ and 5′ GCCCTGGACTGGGGCTGCAT 3′.
The puriﬁed double-stranded PCR product (364 bp) was subjected to
automated DNA sequencing on an ABI PRISM 377.
GM23 – valine to methionine, a G to A substitution in the CH2
region of the γ2 gene –was determined by a nested PCR-RFLP method.
In brief, a 915 bp region of the γ2 gene that incorporates the site for
the allelic substitution was ampliﬁed as described by Brusco et al.
(1995), using the following primers: 5′ AAATGTTGTGTCGAGTGCCC 3′
and 5′ GGCTTGCCGGCCGTGGCAC 3′. A 197 bp segment was further
ampliﬁed from this 915 bp fragment using the following primers: 5′
GCACCACCTGTGGCAGGACC 3′and 5′ TTGAACTGCTCCTCCCGTGG 3′.
Digestion of the ampliﬁed product with the restriction enzyme Nla
III resulted in the following products corresponding to the three
genotypes:GM23þ 90 bp, 63 bp, 44 bp
GM23– 134 bp, 63 bp
GM23þ ,23– 134 bp, 90 bp, 63 bp, 44 bpIgG3 markers GM5,21 and κ chain determinants KM 1,3 were
determined by previously described PCR-RFLP methods (Balbín
et al., 1994; Moxley and Gibbs, 1992).
FcγRIIa and FcγRIIIa genotyping
A change in the nucleotide at position 497 of FcγRIIa gene from
A to G results in change of amino acid histidine to arginine (H/R131).
A change in the nucleotide at position 559 of the FcγRIIIa gene from
T to G results in phenylalanine to valine substitution (F/V158) in the
membrane proximal IgG like domain of FcγRIIIa. The FcγRIIa alleles
were determined by a previously described PCR-RFLP method (Jiang
et al., 1996). The FcγRIIIa alleles were determined by the TaqMan® SNP
Genotyping Assays supplied by Applied Biosystems, following manu-
facturer’s protocols.
Statistical analyses
Cox proportional hazards models were used to estimate the
hazard ratios of HIV1 infection for the various genotypes, account-
ing for the case-cohort sampling scheme. Estimates and variances
were calculated using a method developed by Lin and Ying (1993).
FDRs for all possible pairs of interactions in models using white or
all participants, dominant or additive genetic effect models, were
calculated according to Benjamini and Hochberg (1995). In the
dominant genetic models, genotypes were coded as indicator
variables, where a value of 0 was given to the most common
genotype and 1 to the other possible genotype combinations.
In the additive genetic models, genotypes were coded as 0,1,2 and
treated as a continuous variable in the regression. Two effect
models were considered: marginal genetic effect models esti-
mated the effect of a single genotype on the risk of infection
adjusting for confounders, and interaction models estimated the
potentially epistatic effect of pairs of genotypes on the risk of
infection, or potential modiﬁcation of vaccine effect by genotypes.
J.P. Pandey et al. / Virology 441 (2013) 70–7474Models were adjusted for baseline confounders of risk identiﬁed
previously (Duerr et al., 2012), including indicators for treatment
arm, age (≤30), HSV-2 infection, North America region, Ad5 titer
(≥18), self-reported circumcision status, any drug use, number of
male partners (44), unprotected insertive anal sex, and unpro-
tected receptive anal sex. Ten participants were missing at least
one confounding variable; in these participants missing covariates
were coded as being in the riskier category in the regression
analysis. Models were ﬁt separately for white male participants
only, or all males but adjusting for race categories, including white,
black, mestizo/mestiza and other ethnicity.Acknowledgments
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